Printer Friendly

IMMUCOR REPORTS SECOND QUARTER RESULTS

 NORCROSS, Ga., Jan. 11 /PRNewswire/ -- Immucor, Inc. (NASDAQ-NMS: BLUD), maker of blood bank reagent systems and related products, announced today net income for the three months ended Nov. 30, 1993, totaled $432,060 compared to $559,245 a year ago.
 Earnings per share for the three month period were $.06 compared to $.08 per share last year. For the six month period ended Nov. 30, 1993, net income totaled $1,000,016 compared to $1,550,628 for the six month period last year. Earnings per share totaled $.13 vs. $.21 last year.
 Net sales t?he three months ended Nov. 30, 1993, were $7,857,577 compared to $7,570,962 last year, and for the six month period, net sales totaled $15,445,131 vs. $15,182,927 last year.
 Commenting on second quarter results, Edward L. Gallup, president of Immucor, said, "Research and development expenses included $604,000 of funding for our previously announced, automated blood bank instrument project, compared to $357,000 last year, or approximately $.02 per share in additional after tax expense for the quarter."
 Gallup also noted: "Compared to last year, gross profit, as a percentage of sales revenue, declined due to increased pricing pressure on the company's products and the negative impact of foreign exchange rates. However, this decline was partially offset by cost saving measures implemented earlier in the year which reduced second quarter operating expenses as compared to last year."
 Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion.
 IMMUCOR, INC.
 Statements of Income
 (Unaudited)
 Three Months Ended Six Months Ended
 11/30/93 11/30/92 11/30/93 11/30/92
 Net sales $7,857,577 $7,570,962 $15,445,131 $15,182,927
 Cost of sales 3,480,842 2,706,127 6,341,260 5,454,013
 Gross profit 4,376,735 4,864,835 9,103,871 9,728,914
 Research and development:
 Instrument 603,649 357,336 1,201,691 357,336
 General 105,188 116,376 218,729 218,833
 Selling, general and
 administrative 2,930,545 3,323,994 6,045,196 6,649,773
 Total operating
 expenses 3,639,382 3,797,706 7,465,616 7,225,942
 Income from
 operations 737,353 1,067,129 1,638,255 2,502,972
 Other income 89,371 42,179 127,139 303,559
 Interest expense (166,061) (225,494) (318,377) (410,930)
 Other expense (20,172) (13,945) (21,689) (26,267)
 Total other (96,862) (197,260) (212,927) (133,638)
 Income before income
 taxes 640,491 869,869 1,425,328 2,369,334
 Provision for
 income taxes 208,431 310,624 425,312 818,706
 Net income $432,060 $559,245 $1,000,016 $1,550,628
 Net income per
 common and common
 equiv. share $0.06 $0.08 $0.13 $0.21
 -0- 1/11/94
 /CONTACT: Richard J. Still, vice president-finance, Immucor, Inc., 404-441-2051/
 (BLUD)


CO: Immucor, Inc. ST: Georgia IN: MTC SU: ERN

JS-BR -- AT001 -- 0825 01/11/94 08:02 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1994
Words:546
Previous Article:SILICON GRAPHICS RECEIVES ISO CERTIFICATION FOR MANUFACTURING QUALITY
Next Article:SUNTRUST 1993 NET $473.7 MILLION; $119.2 MILLION FOR FOURTH QUARTER
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters